Skip to main content
Transcenta Holding Limited logo

Transcenta Holding Limited — Investor Relations & Filings

Ticker · 6628 ISIN · KYG9005B1041 HKEX Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2023-05-08 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6628

About Transcenta Holding Limited

http://www.transcenta.com

Transcenta Holding Limited is a clinical-stage global biotherapeutics company specializing in the discovery, research, development, and manufacturing of differentiated antibody-based therapeutics. The company operates a fully integrated platform, utilizing a unique antibody generation platform based on Immune Tolerance Breaking Technology to generate candidate leads. Its robust pipeline includes therapeutic antibody molecules targeting oncology and selected non-oncology indications, such as bone and kidney disorders. The company employs advanced bioprocessing technologies, including perfusion-based continuous bioprocessing, to accelerate process development and reduce manufacturing costs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON COMPANY'S PRESENTATION OF TWO CLINICAL TRIAL PROGRESS AT ASCO 2023
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Transcenta Holding Limited providing a business update on the company's presentation of clinical trial progress at the ASCO 2023 Annual Meeting. It details the content of two clinical trial posters to be presented, including study titles, session times, and authors. The document does not contain financial statements, earnings data, or regulatory filings. It is not an annual or interim report, audit report, or earnings release. It is also not a proxy, voting result, or management change announcement. The document is a business update announcement related to clinical trial progress and presentations, which fits best under the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories. The document length is about 5479 characters, which is sufficient for a substantive announcement but does not constitute a full report or presentation. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-05-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report on movements in securities for Transcenta Holding Limited, including authorized and issued share capital, share options, awards, repurchases, and confirmations related to securities issued. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules, specifically Chapter 19B. The content focuses on share capital changes, share options, and confirmations of compliance with listing requirements. It is not a full annual or interim financial report, nor an earnings release, audit report, or management discussion. It is a regulatory filing related to share capital movements and compliance confirmations, typical of a regulatory announcement to the stock exchange rather than a financial report or presentation. The document length is substantial (over 12,000 characters) and contains detailed tabular data on share movements, but it is not a financial statement or management report. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-05-05 English
Next Day Disclosure Returns
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Transcenta Holding Limited. It includes detailed tables of repurchases of shares, dates, quantities, prices, and confirmations that these transactions comply with listing rules of the Stock Exchange of Hong Kong. The document is a regulatory disclosure about share repurchases and capital changes, not a full financial report or earnings release. It is not an announcement of a report publication but a substantive regulatory filing about share capital changes and repurchases. This fits the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares.
2023-05-03 English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON COMPLETION OF ENROLLMENT IN COHORTS C AND G OF CHINA PHASE II CLINICAL STUDY OF OSEMITAMAB (TST001) IN COMBINATION WITH CAPOX WITH OR WITHOUT NIVOLUMAB AS FIR
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Transcenta Holding Limited regarding a business update on the completion of enrollment in clinical study cohorts for a drug candidate. It provides detailed information about the clinical trial phases, patient enrollment, and future plans for Phase III trials. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The content focuses on business progress and clinical development updates rather than financial results or governance changes. It is not a report publication announcement since it contains substantive business update content rather than just announcing a report's availability. The document is best classified as a general regulatory announcement about business progress, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2023-05-03 English
Next Day Disclosure Returns
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Transcenta Holding Limited. It includes detailed information on repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules. The document is a regulatory disclosure about share repurchases and capital changes, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive data. The content fits the category of 'Transaction in Own Shares' (POS), which covers company buybacks or sales of its own shares.
2023-05-02 English
NOTIFICATION LETTER AND REQUEST FORM TO REGISTERED HOLDERS
Report Publication Announcement Classification · 100% confidence The document is a notification letter dated 27 April 2023 from Transcenta Holding Limited to its shareholders. It announces the publication of the company's Environmental, Social and Governance (ESG) Report for the year ended 31 December 2022 on the company's and HKEX's websites. The letter provides instructions on how shareholders can access the report online or request a printed copy. The document does not contain the ESG report itself but serves as a notification of its availability. The document length is 6118 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, such a notification of publication of a report is classified as a Report Publication Announcement (RPA), not as the ESG report itself (which would fall under Environmental & Social Information (SR) if the full report were provided).
2023-04-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.